Clinical trials: Goal Achievement
Dyslipidemia
Survey of Lipid Goal Attainment and Mortality in Patients With High Cardiovascular Risk in Thailand
The first phase of the study is a hospital-based cross-sectional, epidemiological survey. The required sample size is 1,260 patients from 50 hospitals across Thailand.
- Trial name
- NCT00684151
- Where
- 49 sites in Thailand
- Volunteers
- 1,240 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
- Trial name
- NCT02972632
- Testing
- Vortioxetine
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Takeda
Hemophilia A
Goal Attainment and Physical Activity in People With Hemophilia A
This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan.
- Trial name
- ACTIVIIITY (NCT06530030)
- Testing
- efanesoctocog alfa
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sanofi
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with…
- Trial name
- GAUSS-3 (NCT01984424)
- Testing
- Atorvastatin, Ezetimibe
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 511 people
- Sponsor
- Amgen
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with…
- Trial name
- GAUSS (NCT01375764)
- Testing
- Evolocumab, Ezetimibe
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Chronic Pain
The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement
The purpose of this study is to assess the effectiveness and tolerability of Fentanyl matrix in chronic non-cancer pain.
- Trial name
- NCT01688583
- Testing
- Fentanyl matrix
- Where
- 11 sites in South Korea
- Volunteers
- 410 people
- Sponsor
- Janssen Korea, Ltd., Korea
Stable Angina, Hypertension
Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension
This is a multicenter survey of Russian data on target heart rate achievement in patients with stable angina and arterial hypertension who are currently treated with beta-blockers for at least 2 months and with no dose change for…
- Trial name
- Athena (NCT01321242)
- Where
- 6 sites in Russia
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in…
- Trial name
- GAUSS-4 (NCT02634580)
- Testing
- Evolocumab, Ezetimibe
- Where
- 35 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Amgen
Cardiovascular Risk
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)
To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.
- Trial name
- C2 -CORVUS (NCT00921752)
- Where
- 26 sites in Hungary
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia
The purpose of the study is to determine whether an Internet based compliance tool is superior to common diet counselling in patients with hypercholesterolemia.
- Trial name
- NCT00240357
- Testing
- Lifestyle Regulation
- Where
- 109 sites in Denmark
- Volunteers
- 1,175 people
- Sponsor
- AstraZeneca
Dyslipidemias
Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study
To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin…
- Trial name
- AT GOAL (NCT00540293)
- Testing
- Atorvastatin
- Where
- 20 sites in South Korea
- Volunteers
- 425 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Moderate to Severe Plaque Psoriasis
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
This study estimates the treatment goal achievement rate, depicts the implementation of the Progressive Psoriasis Initiative (PPI) recommendations regarding treatment modifications and transitioning, and assesses patient…
- Trial name
- CONCORDIA (NCT02713295)
- Where
- 43 sites in Greece
- Volunteers
- 273 people
- Sponsor
- AbbVie
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol…
- Trial name
- GAUSS-2 (NCT01763905)
- Testing
- Evolocumab, Ezetimibe
- Where
- 58 sites in United States, Australia and 12 more
- Volunteers
- 307 people
- Sponsor
- Amgen
Dyslipidemia
Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea
This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients
- Trial name
- CRESENDO (NCT01372956)
- Where
- 20 sites in South Korea
- Volunteers
- 4,950 people
- Sponsor
- AstraZeneca
Hemophilia A
GAS-Hem Feasibility Study
The purpose of this study is to investigate the feasibility and acceptability of the Standardized Goal Attainment Scaling menu for Hemophilia (GAS-Hem) as a patient reported outcome (PRO) measure to monitor clinical progress in…
- Trial name
- NCT02674997
- Testing
- Factor VIII
- Where
- 4 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Baxalta now part of Shire
Primary Hypercholesterolaemia
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance.
- Trial name
- NCT00396240
- Testing
- Rosuvastatin, Initiatives to improve compliance
- Volunteers
- 1,294 people
- Sponsor
- AstraZeneca
PCI Patients
Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients
Most PCI patients are at very high cardiovascular (CV) risk, and as such here is an increased need for intensive lipid management in Percutaneous Coronary Intervention (PCI) patients and the population is well suited to…
- Trial name
- NCT02561845
- Testing
- rosuvastatin
- Sponsor
- AstraZeneca
Upper Limb Spasticity
Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice
The primary purpose for this study is to understand the effect of botulinum toxin as a treatment integrated in the management of spasticity (stiffness) in the arm and/or hand, arising from any neurological condition.
- Trial name
- ULIS III (NCT02454803)
- Where
- 57 sites in United States, Australia and 12 more
- Volunteers
- 1,004 people
- Sponsor
- Ipsen
Head and Neck Cancer
Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002659
- Testing
- cisplatin-e therapeutic implant
- Where
- 28 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Matrix Pharmaceutical
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes
This study is conducted in Europe. This observational study is aimed to reflect the post-authorisation experience with insulin analogue (biphasic insulin aspart 30) when used under normal clinical practice conditions in Serbia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- EFFECTIVE (NCT00699179)
- Testing
- biphasic insulin aspart 30
- Where
- Serbia and Montenegro
- Volunteers
- 2,308 people
- Sponsor
- Novo Nordisk A/S